{"id":71446,"date":"2026-05-20T11:50:00","date_gmt":"2026-05-20T11:50:00","guid":{"rendered":"https:\/\/medsbase.com\/aod-9604\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aod-9604","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/aod-9604\/","title":{"rendered":"AOD-9604 (Droga Anti-Obesidade 9604 \/ Tyr-hGH 177-191)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 AOD-9604?<\/h3>\n<p style=\"margin: 0;\"><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d, CAS 221231-10-3) \u00e9 um pept\u00eddeo sint\u00e9tico de 16 amino\u00e1cidos desenvolvido pela <strong>Metabolic Pharmaceuticals Ltd<\/strong> (Austr\u00e1lia) no final dos anos 1990 como um an\u00e1logo estabilizado do fragmento lipol\u00edtico C-terminal do horm\u00f4nio de crescimento humano. Sequ\u00eancia Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa, com uma extens\u00e3o de tirosina N-terminal que estabiliza o fragmento parental hGH 177\u2013191, e uma ponte dissulfeto intramolecular Cys7\u2013Cys14). F\u00f3rmula molecular C, PM 1815,1 Da. Em pesquisas publicadas in vitro e em roedores, o AOD-9604 mant\u00e9m a<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>, MW 1815.1 Da. In published in-vitro and rodent studies AOD-9604 retains the <strong>atividade lipol\u00edtica e anti-lipog\u00eanica<\/strong> da mol\u00e9cula parental de hGH, mas n\u00e3o <em>n\u00e3o<\/em> bind the GH receptor \u2014 so it does not induce IGF-1, does not activate growth-axis JAK2\/STAT5 signalling, and does not produce the growth-promoting effects of full-length HGH. Failed Phase IIb obesity trial (2007); now used as a pharmaceutical-grade peptide. <em>For clinical studies use only.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Synthetic 16-amino-acid peptide; stabilised C-terminal hGH-fragment analogue; lipolytic \/ anti-lipogenic peptide (decoupled from GH-receptor binding)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">AOD-9604 (\u201cAnti-Obesity Drug 9604\u201d; sin\u00f4nimos: Tyr-hGH 177-191; H-Tyr-(177-191 hGH fragment)-OH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">221231-10-3 (refer\u00eancia can\u00f4nica Sigma-Aldrich, MedKoo, ChemicalBook)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1815.1 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (letra \u00fanica: YLRIVQCRSVEGSCGF; 16 amino\u00e1cidos). A ponte dissulfeto intramolecular Cys7\u2013Cys14 forma uma estrutura c\u00edclica que imita a geometria dissulfeto da regi\u00e3o parental hGH 182\u2013189. A tirosina N-terminal \u00e9 uma adi\u00e7\u00e3o sint\u00e9tica (n\u00e3o presente na hGH nativa 177\u2013191) que estabiliza o fragmento contra degrada\u00e7\u00e3o proteol\u00edtica amino-terminal.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Lip\u00f3lise mecanicamente desacoplada<\/strong>. O AOD-9604 N\u00c3O se liga ao receptor de GH (GHR) \u2014 a superf\u00edcie de liga\u00e7\u00e3o do GHR da hGH nativa est\u00e1 na por\u00e7\u00e3o N-terminal (regi\u00e3o dos res\u00edduos 1\u2013120), ausente no fragmento 176\u2013191. A atividade lipol\u00edtica\/anti-lipog\u00eanica \u00e9 considerada mediada via sinaliza\u00e7\u00e3o do receptor \u03b23-adren\u00e9rgico e ativa\u00e7\u00e3o direta da lipase sens\u00edvel a horm\u00f4nio (HSL) do adip\u00f3cito via cAMP-PKA. O mecanismo permanece incompletamente caracterizado na literatura publicada \u2014 n\u00e3o h\u00e1 um \u00fanico receptor confirmado para o fragmento lipol\u00edtico C-terminal.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4 minutos (muito curto \u2014 impulsionado por truncamento proteol\u00edtico N-terminal apesar da tirosina estabilizadora). Esta meia-vida curta \u00e9 uma das principais hip\u00f3teses para o fato de o ensaio de obesidade Fase IIb (2007) n\u00e3o ter alcan\u00e7ado os pontos finais de perda de peso \u2014 o fragmento \u00e9 degradado antes que a exposi\u00e7\u00e3o suficiente ao receptor possa se acumular no tecido alvo.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC); espectrometria de massa MALDI-TOF confirma 1815.1 Da. COA dispon\u00edvel mediante solicita\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sol\u00favel em \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril, PBS e \u00e1cido ac\u00e9tico 0,1% a \u22655 mg\/mL; facilmente sol\u00favel em DMSO a \u226550 mg\/mL para prepara\u00e7\u00e3o de estoque in vitro. A ponte dissulfeto Cys7\u2013Cys14 restringe a geometria do pept\u00eddeo, mas n\u00e3o impede a solubilidade aquosa.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C n\u00e3o aberto para estoque de trabalho de curto prazo; \u221220 \u00b0C para armazenamento de longo prazo (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). Aquoso reconstitu\u00eddo: 2\u20138 \u00b0C, usar dentro de ~30 dias. Proteger da luz. Evitar ciclos repetidos de congelamento-descongelamento da solu\u00e7\u00e3o reconstitu\u00edda \u2014 a ponte dissulfeto \u00e9 est\u00e1vel para um \u00fanico ciclo de congelamento-descongelamento, mas ciclos cumulativos podem causar desarranjo de tiol livre e agrega\u00e7\u00e3o parcial.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 AOD-9604?<\/h2>\n<p><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d; CAS 221231-10-3) \u00e9 um pept\u00eddeo sint\u00e9tico de 16 amino\u00e1cidos desenvolvido por <strong>Metabolic Pharmaceuticals Ltd<\/strong> na Monash University em Melbourne, Austr\u00e1lia, a partir do final dos anos 1990. \u00c9 um an\u00e1logo estabilizado do fragmento lipol\u00edtico C-terminal do horm\u00f4nio de crescimento humano nativo (res\u00edduos 177\u2013191), ao qual foi adicionada uma tirosina N-terminal para retardar a degrada\u00e7\u00e3o proteol\u00edtica amino-terminal. Sequ\u00eancia Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), com a ponte dissulfeto intramolecular nativa Cys182\u2013Cys189 da hGH parental preservada como Cys7\u2013Cys14 dentro da numera\u00e7\u00e3o do fragmento. Peso molecular 1815.1 g\/mol, f\u00f3rmula emp\u00edrica C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. The pharmacological logic behind AOD-9604 is one of the cleanest examples of structure-function dissection in HGH peptide studies. Native full-length human growth hormone (191 amino acids) has at least two distinct biological activities: <strong>efeitos anab\u00f3licos\/promotores de crescimento<\/strong> (mediados pelo receptor de GH, sinaliza\u00e7\u00e3o JAK2\/STAT5 e produ\u00e7\u00e3o subsequente de IGF-1) e <strong>efeitos lipol\u00edticos\/anti-lipog\u00eanicos<\/strong> (mediated through a separate, incompletely-characterised mechanism that does not require GH-receptor engagement). The Monash group&#8217;s hypothesis was that the lipolytic activity is encoded in the C-terminal region of the molecule \u2014 and that a synthetic peptide encompassing just that region might retain the fat-mobilising activity while losing the growth-axis-engaging activity. This proved correct in published in-vitro and rodent studies: the 176\u2013191 fragment retains lipolytic and anti-lipogenic activity in adipocyte culture and DIO mouse models, but does not bind GHR, does not activate JAK2\/STAT5, and does not induce IGF-1. AOD-9604 progressed through multiple Phase I and Phase II clinical trials in the early-to-mid 2000s, culminating in a 28-week Phase IIb obesity trial (~500 patients) completed in 2007 by Metabolic Pharmaceuticals. The trial did not achieve its primary weight-loss endpoint, and the obesity-pharmacology development programme was discontinued. AOD-9604 subsequently entered the studies-peptide and unregulated-supplement markets, where it has remained one of the most-cited &#8220;fat-loss peptides&#8221; in non-clinical literature. The compound retains studies utility as the canonical pharmacological tool for studying GHR-decoupled lipolysis, the C-terminal hGH fragment biology, and the structure-function basis of HGH&#8217;s multiple activities. A note on nomenclature: AOD-9604 and &#8220;<a href=\"https:\/\/medsbase.com\/pt-br\/hgh-fragment-176-191\/\">Fragmento de HGH 176-191<\/a>&#8221; are often used interchangeably in the supplier and studies-peptide marketplace. Strictly, AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal Tyr stabilisation. &#8220;HGH Fragment 176-191&#8221; (CAS 66004-57-7 per some references) is the older, un-stabilised hGH 177\u2013191 fragment that AOD-9604 was derived from. Both share the same YLRIVQCRSVEGSCGF amino-acid sequence in many supplier preparations \u2014 but the AOD-9604 designation specifically identifies the registered Metabolic-Pharmaceuticals compound. Users should consult the COA to confirm which form a given supplier batch corresponds to. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Lip\u00f3lise Desacoplada do GHR<\/h2>\n<p>AOD-9604&#8217;s mechanism is among the most-discussed in HGH peptide studies:<\/p>\n<ul>\n<li><strong>Aus\u00eancia de liga\u00e7\u00e3o ao receptor de GH<\/strong> \u2014 A superf\u00edcie de liga\u00e7\u00e3o ao GHR do hGH nativo est\u00e1 contida na metade N-terminal da mol\u00e9cula (regi\u00e3o de res\u00edduos 1\u2013120), que est\u00e1 ausente no fragmento AOD-9604\/176\u2013191. Como resultado, o AOD-9604 N\u00c3O se liga ao receptor do horm\u00f4nio de crescimento (GHR), N\u00c3O ativa a sinaliza\u00e7\u00e3o JAK2\/STAT5, N\u00c3O induz a produ\u00e7\u00e3o hep\u00e1tica de IGF-1 e N\u00c3O produz os efeitos promotores de crescimento, estimulantes de condr\u00f3citos ou contra-regulat\u00f3rios da insulina da mol\u00e9cula <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-191aa\/\">HGH 191AA<\/a> original. Esta \u00e9 a propriedade farmacol\u00f3gica <em>negativa<\/em> pharmacological property and the basis for AOD-9604&#8217;s studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>sinaliza\u00e7\u00e3o do receptor \u03b23-adren\u00e9rgico (hipotetizada)<\/strong> \u2014 The leading mechanistic hypothesis for AOD-9604&#8217;s lipolytic activity is that it engages the \u03b23-adrenergic receptor (ADRB3) on adipocytes, either directly as an allosteric modulator or via an intermediate pathway. Published in-vitro has demonstrated that AOD-9604&#8217;s lipolytic effect is blunted by \u03b23-adrenergic antagonists, supporting the \u03b23-AR hypothesis, although direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated in radioligand-binding assays. The mechanism remains incompletely characterised \u2014 a feature users should be aware of when interpreting published AOD-9604 results.<\/li>\n<li><strong>Ativa\u00e7\u00e3o da lipase horm\u00f4nio-sens\u00edvel (HSL)<\/strong> \u2014 A jusante do envolvimento do receptor, o AOD-9604 foi relatado como ativador da lipase horm\u00f4nio-sens\u00edvel dos adip\u00f3citos por meio da fosforila\u00e7\u00e3o mediada pela PKA (a rota can\u00f4nica de ativa\u00e7\u00e3o da lip\u00f3lise), impulsionando a hidr\u00f3lise de triglicer\u00eddeos em glicerol e \u00e1cidos graxos livres. O aumento na libera\u00e7\u00e3o de \u00e1cidos graxos livres na circula\u00e7\u00e3o foi documentado em trabalhos in vivo publicados em roedores ap\u00f3s a administra\u00e7\u00e3o de AOD-9604.<\/li>\n<li><strong>Atividade antilipog\u00eanica<\/strong> \u2014 Al\u00e9m de promover a lip\u00f3lise, o AOD-9604 foi relatado como supressor da lipog\u00eanese de novo em adip\u00f3citos cultivados \u2014 reduzindo a atividade da acetil-CoA carboxilase (ACC) e da sintase de \u00e1cidos graxos (FAS) em ensaios de diferencia\u00e7\u00e3o de 3T3-L1. O perfil combinado de aumento da lip\u00f3lise\/redu\u00e7\u00e3o da lipog\u00eanese \u00e9 a farmacologia can\u00f4nica de \u201cmobiliza\u00e7\u00e3o de gordura\u201d que o programa original da Metabolic-Pharmaceuticals foi projetado para engajar.<\/li>\n<li><strong>Cartilage \/ osteoarthritis studies (secondary indication)<\/strong> \u2014 Following the failure of the obesity programme, AOD-9604 was repositioned for evaluation in osteoarthritis studies, with the hypothesis that chondroprotective effects of the parent hGH might be partially retained in the C-terminal fragment. Published in-vitro and small-animal has reported chondrocyte-protective effects, although no large clinical trial in this indication has been completed.<\/li>\n<li><strong>O problema da meia-vida de 4 minutos<\/strong> \u2014 AOD-9604&#8217;s plasma half-life is approximately 4 minutes, driven by rapid amino-terminal proteolytic truncation despite the N-terminal Tyr stabilisation. This very short pharmacokinetic profile is one of the leading hypotheses for why the Phase IIb obesity trial did not achieve weight-loss endpoints \u2014 the fragment is degraded before sufficient receptor exposure can accumulate in target adipose tissue under once-daily SC dosing. Newer peptides that target the same lipolysis-axis biology with longer half-lives (modified hGH fragments with PEG-stabilisation, fragment-Fc fusion proteins) are in earlier-stage studies and not commercially available.<\/li>\n<\/ul>\n<p>The combination of mechanistically clean GHR-decoupling and disappointing in-vivo half-life makes AOD-9604 a useful tool with a clear pharmacological story but a documented translational limitation. Published studies dosing in rodents is typically 100\u20131,000 \u00b5g\/kg\/d SC, with the higher end of this range used to overcome the short half-life by saturating clearance. In cell-culture work, micromolar concentrations are used because of the short biological half-life of the fragment in culture medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AOD-9604 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia da lip\u00f3lise desacoplada do GHR<\/strong> \u2014 the canonical tool for studying the lipolytic \/ anti-lipogenic activity of the C-terminal hGH fragment in isolation from GH-axis signalling; standard reference compound for any new &#8220;fat-loss-only&#8221; hGH-fragment studies<\/li>\n<li><strong>Structure-function studies of HGH<\/strong> \u2014 AOD-9604 is one of the cleanest examples of pharmacological structure-function dissection of the multi-activity HGH molecule; used in published studies that maps the lipolytic-domain residues of native HGH<\/li>\n<li><strong>Adipocyte biology and lipolysis studies<\/strong> \u2014 drives lipolysis in cultured 3T3-L1 and primary adipocyte preparations; used in studies on the regulation of adipocyte hormone-sensitive lipase, lipid droplet remodelling, and brown \/ beige adipocyte biology<\/li>\n<li><strong>Farmacologia do receptor \u03b23-adren\u00e9rgico (indireta)<\/strong> \u2014 AOD-9604&#8217;s \u03b23-AR-dependence (in some published studies) makes it useful as an indirect probe of \u03b23-AR-coupled lipolysis pathways, alongside direct \u03b23-AR agonists (CL-316,243, mirabegron)<\/li>\n<li><strong>Diet-induced obesity (DIO) rodent studies<\/strong> \u2014 published 4\u20138 week dosing protocols (100\u20131,000 \u00b5g\/kg\/d SC) in DIO mice and rats have been reported to reduce fat-mass without affecting lean-mass or IGF-1 levels; standard tool for the &#8220;lipolytic-only&#8221; component of fat-loss pharmacology<\/li>\n<li><strong>Cartilage \/ chondrocyte studies<\/strong> \u2014 used in published in-vitro chondrocyte and small-animal osteoarthritis models for chondroprotective evaluation; secondary studies indication following the discontinuation of the obesity programme<\/li>\n<li><strong>Farmacologia comparativa vs HGH 191AA e Fragmento de HGH 176-191<\/strong> \u2014 compara\u00e7\u00f5es publicadas de AOD-9604 vs HGH de comprimento total e o fragmento 176-191 n\u00e3o estabilizado caracterizaram os perfis diferenciais de liga\u00e7\u00e3o ao GHR, indu\u00e7\u00e3o de IGF-1 e lip\u00f3lise; AOD-9604 est\u00e1 no extremo \u201capenas lipol\u00edtico, sem eixo de crescimento\u201d desse espectro<\/li>\n<li><strong>Plasma-stability and protease-resistance studies<\/strong> \u2014 the 4-minute half-life makes AOD-9604 a useful reference compound for protease-resistance studies; newer modified analogues (PEG-stabilised, fragment-Fc fusion, alternative N-terminal cap modifications) are benchmarked against AOD-9604 in early-stage development studies<\/li>\n<\/ul>\n<p>For broader context on HGH-axis and fat-loss peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-fragment-176-191\/\">Fragmento de HGH 176-191<\/a> (o fragmento parental n\u00e3o estabilizado \u2014 compara\u00e7\u00e3o direta), <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-191aa\/\">HGH 191AA<\/a> (a mol\u00e9cula parental de comprimento total \u2014 para farmacologia comparativa), <a href=\"https:\/\/medsbase.com\/pt-br\/tesamorelin\/\">Tesamorelina<\/a> (an\u00e1logo de GHRH \u2014 estimula\u00e7\u00e3o do eixo HGH a montante), <a href=\"https:\/\/medsbase.com\/pt-br\/sermorelin\/\">Sermorelina<\/a> (an\u00e1logo de GHRH 1-29), e <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo metab\u00f3lico derivado mitocondrial). Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">peptides &amp; compounds catalog<\/a>, ou consulte o <a href=\"https:\/\/medsbase.com\/pt-br\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> e <a href=\"https:\/\/medsbase.com\/pt-br\/best-growth-hormone-peptides\/\">growth-hormone peptides<\/a> hubs. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks AOD-9604 in three lyophilized vial sizes calibrated to typical in-vitro and in-vivo protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cultura de c\u00e9lulas in vitro e titula\u00e7\u00e3o de curta dura\u00e7\u00e3o in vivo \u2014 ensaios de lip\u00f3lise em adip\u00f3citos 3T3-L1, farmacologia de adip\u00f3citos prim\u00e1rios, pain\u00e9is de dose-resposta, titula\u00e7\u00e3o murina de coorte \u00fanica<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard mid-strength \u2014 diet-induced obesity rodent protocols (100\u2013500 \u00b5g\/kg\/d SC for 4\u20138 weeks), chondrocyte \/ osteoarthritis studies, multi-cohort sample sizes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-cycle \/ high-dose protocols (up to 1 mg\/kg\/d SC), large-cohort DIO studies, multi-arm structure-function comparisons; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical entity (lyophilized AOD-9604, \u226599% HPLC purity, MALDI-TOF mass-confirmed at 1815.1 Da). The 10\u00a0mg vial provides the lowest per-mg cost for large in-vivo protocols (a single 10\u00a0mg vial supports approximately 50 days of 200 \u00b5g\/kg\/d dosing in a 25-g mouse, or about 10 days at 1\u00a0mg\/kg\/d in a 30-g rat). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Como Ele Compara \u2014 AOD-9604 vs Fragmento 176-191 do HGH<\/h2>\n<p>AOD-9604 e <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-fragment-176-191\/\">Fragmento de HGH 176-191<\/a> are the two HGH C-terminal fragment peptides in this catalogue, and they sit very close together on the structure-function spectrum. AOD-9604 is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal tyrosine extension that adds protease-stability. The un-stabilised HGH Fragment 176-191 lacks the N-terminal Tyr and has a slightly shorter half-life in culture \/ in-vivo, but is otherwise mechanistically identical. The two compounds are often used interchangeably in supplier listings \u2014 the differentiation matters for rigorous pharmacology studies, less so for cell-culture stimulation work. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AOD-9604<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Fragmento de HGH 176-191<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">221231-10-3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">66004-57-7<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sequ\u00eancia (letra \u00fanica)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa; com estabiliza\u00e7\u00e3o N-terminal Tyr)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa) ou LRIVQCRSVEGSCGF (15 aa, n\u00e3o estabilizado) dependendo do lote do fornecedor; consulte o COA<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1815.1 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1817.06 g\/mol (grau fornecedor 16-aa) ou 1654 g\/mol (15-aa n\u00e3o estabilizado)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origem<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Metabolic Pharmaceuticals Ltd (Universidade Monash, Austr\u00e1lia, final dos anos 1990)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Earlier academic studies-peptide preparation, pre-dating AOD-9604<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~4 minutos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2\u20133 minutos (mais curto, menos est\u00e1vel \u00e0 protease)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Liga\u00e7\u00e3o ao receptor de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nenhum \u2014 n\u00e3o ativa o eixo GHR\/JAK2\/STAT5\/IGF-1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nenhum \u2014 mesma propriedade; ambos s\u00e3o fragmentos desacoplados do GHR<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Hist\u00f3rico de ensaios cl\u00ednicos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ensaio de fase IIb para obesidade (~500 pacientes, 2007) n\u00e3o atingiu o endpoint prim\u00e1rio; programa descontinuado<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nenhum programa formal de desenvolvimento cl\u00ednico<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ligeiramente preferido para trabalhos in vivo devido \u00e0 meia-vida marginalmente mais longa; composto de refer\u00eancia para compara\u00e7\u00f5es de estrutura-fun\u00e7\u00e3o<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ensaios de lip\u00f3lise in vitro em cultura de c\u00e9lulas onde a meia-vida curta \u00e9 menos limitante<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on rigorous structure-function HGH-fragment pharmacology, AOD-9604 with its registered CAS \/ known origin is the cleaner reference. For exploratory in-vitro lipolysis work where the precise origin matters less, <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-fragment-176-191\/\">Fragmento de HGH 176-191<\/a> is the more economical option. For studies that needs the full HGH pharmacology including GH-receptor \/ IGF-1 axis engagement, see <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-191aa\/\">HGH 191AA<\/a>. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo, congele frascos n\u00e3o abertos a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). A ponte dissulfeto Cys7\u2013Cys14 \u00e9 est\u00e1vel no estado liofilizado e durante armazenamento refrigerado breve. Proteger da luz. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injete \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado). Para um frasco de 2 mg, 1,0 mL de diluente produz uma solu\u00e7\u00e3o de trabalho de 2 mg\/mL; 0,5 mL produz 4 mg\/mL. Para um frasco de 5 mg, 1,0 mL produz 5 mg\/mL; 2,5 mL produz 2 mg\/mL. Para um frasco de 10 mg, 1,0 mL produz 10 mg\/mL (limite pr\u00e1tico de solubilidade em tamp\u00e3o aquoso); 5,0 mL produz 2 mg\/mL. O AOD-9604 dissolve-se rapidamente com agita\u00e7\u00e3o suave \u00e0 temperatura ambiente \u2014 tipicamente em 15\u201330 segundos. Uma vez reconstitu\u00eddo, armazene o frasco a 2\u20138 \u00b0C e use dentro de 30 dias. Proteger da luz. <strong>Evite ciclos repetidos de congelamento-descongelamento do material reconstitu\u00eddo<\/strong> \u2014 o congelamento-descongelamento cumulativo pode causar desarranjo da ponte dissulfeto Cys7\u2013Cys14 e agrega\u00e7\u00e3o parcial. Descartar se aparecer turbidez, part\u00edculas ou mudan\u00e7a acentuada de cor. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>Qual \u00e9 a diferen\u00e7a entre AOD-9604 e o Fragmento 176-191 do HGH?<\/h3>\n<p>AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed registered compound with an N-terminal tyrosine extension that adds amino-terminal protease-stability to the parent hGH 177\u2013191 fragment. &#8220;<a href=\"https:\/\/medsbase.com\/pt-br\/hgh-fragment-176-191\/\">Fragmento de HGH 176-191<\/a>&#8221; (CAS 66004-57-7 per some references) is the earlier, un-stabilised version of the same C-terminal hGH peptide. The two are often used interchangeably in the studies-peptide marketplace, but strictly the AOD-9604 designation identifies the Metabolic-Pharmaceuticals registered analogue with the stabilising Tyr. Both lack GHR binding and both retain the lipolytic activity of the parent hGH C-terminal region. Consult the COA to confirm which sequence form a given batch corresponds to. <\/p>\n<h3>O AOD-9604 \u00e9 o mesmo que o HGH?<\/h3>\n<p>N\u00e3o. O AOD-9604 \u00e9 um fragmento sint\u00e9tico de 16 amino\u00e1cidos do HGH que cobre apenas a regi\u00e3o lipol\u00edtica C-terminal (res\u00edduos 176\u2013191 + Tyr N-terminal). O HGH nativo <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-191aa\/\">HGH 191AA<\/a> is the full-length 191-amino-acid protein. The most important pharmacological difference is that full-length HGH binds the growth hormone receptor (GHR) and activates the JAK2\/STAT5\/IGF-1 axis \u2014 driving the broad growth-promoting and metabolic effects of HGH \u2014 while AOD-9604 does NOT bind GHR and does NOT induce IGF-1. AOD-9604 retains only the lipolytic \/ anti-lipogenic activity of the parent molecule. The two compounds are therefore mechanistically distinct: HGH 191AA for full GH-axis pharmacology, AOD-9604 for lipolysis-only studies. <\/p>\n<h3>Por que o ensaio de fase IIb para obesidade falhou?<\/h3>\n<p>The 28-week Phase IIb obesity trial (~500 patients, completed by Metabolic Pharmaceuticals in 2007) did not achieve its primary weight-loss endpoint relative to placebo. The leading hypotheses in subsequent published analyses are: (1) the very short plasma half-life (~4 minutes) limits cumulative receptor exposure under once-daily SC dosing; (2) the lipolytic effect, while real in mechanistic in-vitro and acute in-vivo experiments, may not translate to net adipose-mass loss in the human metabolic context where compensatory anti-lipolytic signalling dominates over chronic dosing; (3) the in-vivo dose may have been insufficient to overcome the pharmacokinetic constraint. The compound was repositioned for osteoarthritis studies after the obesity programme was discontinued. <\/p>\n<h3>What published dose ranges have been used in rodent studies?<\/h3>\n<p>Published mouse and rat in-vivo protocols typically use 100\u20131,000 \u00b5g\/kg\/d SC, with most published work in the 200\u2013500 \u00b5g\/kg\/d range for 4\u20138 weeks. The higher end of this range (up to 1 mg\/kg\/d) has been used in some publications to overcome the short half-life. In-vitro 3T3-L1 adipocyte assays typically use 1\u201310 \u00b5M. Users should consult primary literature (Ng et\u00a0al. \u2014 Metabolic Pharmaceuticals studies; Heffernan et\u00a0al. \u2014 adipocyte mechanism studies) for species-, model-, and endpoint-specific guidance. <\/p>\n<h3>Qual \u00e9 o status regulat\u00f3rio do AOD-9604 pela WADA?<\/h3>\n<p>AOD-9604 is not on the current WADA Prohibited List under its specific name. However, the broader S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics) explicitly covers growth-hormone fragments and &#8220;GH-axis-related compounds,&#8221; and AOD-9604&#8217;s classification under this broader category has been the subject of regulatory discussion. Users conducting human-subject studies with AOD-9604 should consult the current WADA Prohibited List and applicable jurisdictional regulations directly rather than relying on the absence of a specific name from the list. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre o AOD-9604 e agonistas \u03b23-adren\u00e9rgicos diretos como o mirabegron?<\/h3>\n<p>Mirabegron e CL-316,243 s\u00e3o <em>diretamente<\/em> agonistas do receptor \u03b23-adren\u00e9rgico \u2014 mol\u00e9culas pequenas que se ligam ao s\u00edtio ortot\u00e9rico do \u03b23-AR e ativam a sinaliza\u00e7\u00e3o Gs-cAMP. O AOD-9604 \u00e9 um <em>indireto<\/em> \u03b23-AR engager (in some published studies) \u2014 the lipolytic activity is blunted by \u03b23-AR antagonists, supporting \u03b23-AR-dependence, but direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated. For studies that needs cleanly defined direct \u03b23-AR pharmacology, mirabegron or CL-316,243 are the preferred tools. For studies that needs the broader &#8220;lipolytic-fragment-of-HGH&#8221; pharmacology with its incompletely-characterised mechanism, AOD-9604 is the canonical reference. <\/p>\n<h3>Can AOD-9604 be combined with HGH 191AA, GHRH analogues, or other lipolytic peptides in protocols?<\/h3>\n<p>Sim \u2014 o AOD-9604 visa uma camada diferente da biologia do eixo HGH em rela\u00e7\u00e3o ao HGH de comprimento total <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-191aa\/\">HGH 191AA<\/a> ou os an\u00e1logos de GHRH (<a href=\"https:\/\/medsbase.com\/pt-br\/tesamorelin\/\">Tesamorelina<\/a>, <a href=\"https:\/\/medsbase.com\/pt-br\/sermorelin\/\">Sermorelina<\/a>), and combinations are commonly used in published studies to dissect lipolytic-only contributions from broader GH-axis effects. The most-published combinations are AOD-9604 + HGH 191AA (testing whether the lipolytic component adds to or substracts from full HGH activity); AOD-9604 + <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> (dual fat-loss studies, different mechanisms); AOD-9604 + a GHRH analogue (testing whether endogenous-pulsatile HGH release combined with the lipolytic fragment outperforms either alone). Reconstitute each separately and follow each compound&#8217;s specific storage rules. <\/p>\n<h3>Por que o AOD-9604 \u00e0s vezes \u00e9 listado como 1815.1 Da e outras vezes como 1817 Da?<\/h3>\n<p>A discrep\u00e2ncia reflete a diferen\u00e7a entre a massa monoisot\u00f3pica (1815.1 Da, calculada a partir do is\u00f3topo mais abundante de cada \u00e1tomo) e a massa molecular m\u00e9dia (1817.1 Da, calculada a partir da m\u00e9dia ponderada dos is\u00f3topos naturais de cada \u00e1tomo). Ambos est\u00e3o corretos para a mesma mol\u00e9cula. A espectrometria de massa MALDI-TOF normalmente relata a massa monoisot\u00f3pica para pept\u00eddeos desse tamanho; literatura mais antiga e alguns fornecedores relatam a massa m\u00e9dia. Para fins de COA, o valor de 1815.1 Da \u00e9 a refer\u00eancia can\u00f4nica da Sigma-Aldrich. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HGH-Axis and Fat-Loss Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/hgh-fragment-176-191\/\"><strong>Fragmento de HGH 176-191<\/strong><\/a> \u2014 Fragmento parental n\u00e3o estabilizado \u2014 irm\u00e3o mec\u00e2nico direto, lip\u00f3lise similar desacoplada do GHR<\/li>\n<li><a href=\"\/pt-br\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Mol\u00e9cula parental de comprimento total \u2014 para farmacologia comparativa com engajamento do eixo GH<\/li>\n<li><a href=\"\/pt-br\/tesamorelin\/\"><strong>Tesamorelina<\/strong><\/a> \u2014 An\u00e1logo de GHRH \u2014 estimula\u00e7\u00e3o do eixo HGH a montante<\/li>\n<li><a href=\"\/pt-br\/sermorelin\/\"><strong>Sermorelina<\/strong><\/a> \u2014 GHRH 1-29 analogue \u2014 pituitary endogenous-HGH studies<\/li>\n<li><a href=\"\/pt-br\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived metabolic peptide \u2014 alternative-mechanism fat-loss studies<\/li>\n<li><a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, preservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Fragmento lipol\u00edtico C-terminal hGH 176-191 estabilizado (extens\u00e3o N-terminal Tyr)<br \/>\n\u2705 Desenvolvido pela Metabolic Pharmaceuticals Ltd (Universidade Monash, final dos anos 1990)<br \/>\n\u2705 Desacoplado do GHR \u2014 sem IGF-1, sem JAK2\/STAT5, sem envolvimento do eixo de crescimento<br \/>\n\u2705 Lipol\u00edtico + anti-lipog\u00eanico; dependente de \u03b23-AR (mecanismo n\u00e3o completamente caracterizado)<br \/>\n\u2705 Meia-vida plasm\u00e1tica de ~4 min; Estudo de Fase IIb para obesidade falhou (2007); PM 1815.1, CAS 221231-10-3<\/p>\n<p><strong>AOD-9604<\/strong> contains synthetic Tyr-hGH(177-191) peptide.<\/p>","protected":false},"featured_media":71463,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6500,6499,6502,6503,6289,6501,6494],"class_list":["post-71446","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-anti-obesity-drug","product_tag-aod-9604","product_tag-fat-loss-research","product_tag-ghr-decoupled","product_tag-hgh-fragment","product_tag-lipolytic-peptide","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71463"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71446"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71446"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71446"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}